Baltimore, MD Clinical Trials Report — May 2026

For Baltimore residents considering participation in clinical research, May 2026 presents both urgent opportunities and exciting new avenues for contributing to medical science. Across Baltimore, a significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

Time is Running Out: Trials Closing Soon

A total of 106 clinical trials in Baltimore are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 29 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various neurological conditions, cancers, and chronic pain are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stroke (4 trials)
• Chronic pain (3 trials)
• Breast cancer (3 trials)
• Mild cognitive impairment (3 trials)
• Alzheimer disease (2 trials)
• Pancreatic cancer (2 trials)
• Depression (2 trials)

New Opportunities for Research Participation

This month, Baltimore saw the opening of 17 new clinical trials, a slight decrease from the 22 trials that launched in April 2026. This brings the total number of actively recruiting clinical trials in Baltimore, MD, to 1,450 across 519 research facilities, underscoring the city's robust research landscape.

New trials this month are exploring a range of conditions, with notable additions in:

• ADHD - Attention Deficit Disorder with Hyperactivity
• Allergic Reaction (IgA) Vasculitis
• Colorectal Cancer
• Gastrointestinal Neoplasms / GI Cancer

Drug trials account for the largest share of new studies, with 10 new drug trials, followed by 3 behavioral trials and 2 device trials.

Spotlight on Notable New Trials

May brings several high-profile new trials to Baltimore, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• The Canopy Cancer Collective, LLC is leading NCT07605702, "The Canopy Cancer Collective Clinical Registry Protocol," a large observational registry protocol aiming for 100,000 participants to systematically collect comprehensive data on gastrointestinal cancer patients.
• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is sponsoring NCT07580339, "Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer." This Phase 2 study, involving 30 participants, evaluates the safety and clinical activity of a combined treatment for high-risk rectal cancer.
• Qifeng Zhang is sponsoring NCT07595367, "Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis." This Phase 2 trial aims to enroll 30 participants to study a new agent for a common vascular allergic disease.

Baltimore's Leading Research Hubs

Baltimore is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Johns Hopkins University (155 trials)
• Johns Hopkins Hospital (119 trials)
• Johns Hopkins University/Sidney Kimmel Cancer Center (70 trials)
• University of Maryland (59 trials)
• University of Maryland/Greenebaum Cancer Center (58 trials)
• Sinai Hospital of Baltimore (53 trials)
• University of Maryland Medical Center (49 trials)

These institutions offer a broad spectrum of research, from oncology at Johns Hopkins and the University of Maryland's cancer centers, to diverse medical fields across their main campuses and affiliated hospitals.

Healthy Volunteers: Your Role in Advancing Medicine

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 6 of the 17 new trials launched this month are actively seeking healthy volunteers. Across Baltimore, a total of 225 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Who Can Participate? Demographics and Sponsors

Participation in clinical trials is open to a diverse range of individuals. Of the 17 new trials launched this month, 13 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children, and 1 is female-only. Academic institutions continue to play a vital role in Baltimore's research ecosystem, with Johns Hopkins University (5 trials) and University of Maryland, Baltimore (2 trials) sponsoring the most new studies. Industry sponsors like Novo Nordisk A/S (1 trial) are also driving significant research efforts.

Beyond Baltimore: Nearby Research Options

While Baltimore offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Maryland. Cities with active trials include Bethesda (10 trials), Rockville (3 trials), Lutherville (2 trials), Gaithersburg (1 trial), Germantown (1 trial), Hagerstown (1 trial), Hunt Valley (1 trial), and Pasadena (1 trial).

As we move further into spring, Baltimore's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.